RxDoctor Payments Data

Meghan Barrett

Nurse Practitioner · Nashville, TNNPI 1982392619

Payments from drug & device makers

$2,181in general payments, 2019–2025

Across 88 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$360
  • Regeneron Healthcare Solutions, Inc.$303
  • Insmed, Inc.$275
  • AstraZeneca$221
  • Grifols USA, LLC$152
  • Johnson & Johnson$131
  • plus $739 from 14 others

What the payments were for

  • Food & beverage$2,10396%
  • Education$774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,326
Medicare patients
165
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$140,997
NucalaMepolizumab12$44,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,720
Spiriva RespimatTiotropium Bromide16$9,205
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$8,156
Breo ElliptaFluticasone/Vilanterol18$7,041
Albuterol Sulfate HfaAlbuterol Sulfate50$1,542
Montelukast Sodium25$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$152$140,99712 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta$55$80,22871 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$360$17,36133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →